PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 29, 2026Journal of Clinical Oncology

Interrogation of fibrolamellar cancer to provide clinically relevant insights into therapeutic vulnerabilities.

View Full Paper
Ask AI
Bookmark
Share

Authors

SSSabina A. SchneiderPKPaul KentTSTom Michael Stockwell

Discussion

Loading...

Member takes

Overview

Randomized trial explores therapeutic vulnerabilities in fibrolamellar carcinoma, suggesting novel treatment strategies.

Key Points

  • The study aims to identify therapeutic vulnerabilities in fibrolamellar carcinoma to improve treatment options.
  • Examined 41 FLC specimens using ex vivo analysis of programmed cell death.
  • Assessed 24 drugs for efficacy, measuring the lethal concentration 50% (LC50) and drug synergy.
  • Compared drug activity against data from over 10,000 prior human tumor explant analyses.
  • Vorinostat demonstrated the highest single-agent activity; synergy noted with GEMOX and Lenvatinib in 40% of samples.
  • Previously treated tumors exhibited greater drug resistance, impacting treatment efficacy.
  • Findings indicate metabolic vulnerabilities associated with the DNAJB1-PRKACA genotype in FLC.

Cite This Study

Schneider et al. (2026) studied this question.

synapsesocial.com/papers/6a192e68fab5b468c44176c2https://doi.org/10.1200/jco.2026.44.16_suppl.10041
View Full Paper
Ask AI
Bookmark
Share